Dissociation

DSM5 Severity Measure for Dissociation, Child

The Brief Dissociative Experiences Scale (DES-B)—Modified is an 8-item measure that assesses the severity of dissociative experiences in children ages 11–17. The measure is completed by the child upon receiving a diagnosis of a dissociative disorder (or clinically significant dissociative symptoms) and thereafter, prior to follow-up visits with the clinician. Each item asks the child receiving care to rate the severity of his or her dissociative experiences during the past 7 days.

Total number of questions

8

Administration method

Self-report

Standardized cadence

Every week

Age range

11-17

Language

English

Scoring and interpretation

Each item on the measure is rated on a 5-point scale (0=Not at all; 1=Once or twice; 2=Almost every day; 3=About once a day, and 4=More than once a day). The total score can range from 0 to 32, with higher scores indicating greater severity of dissociative experiences. The clinician is asked to review the score of each item on the measure during the clinical interview and indicate the raw score for each item in the section provided for “Clinician Use.” The raw scores on the 8 items should be summed to obtain a total raw score. In addition, the clinician is asked to calculate and use the average total score. The average total score reduces the overall score to a 5-point scale, which allows the clinician to think of the severity of the child’s brief dissociative experiences in terms of none (0), mild (1), moderate (2), severe (3), or extreme (4). The average total score is calculated by dividing the raw total score by number of items in the measure (i.e., 8). The use of the average total score was found to be reliable, easy to use, and clinically useful to the clinicians in the DSM-5 Field Trials.

Reliability and validity

Additional information

Start delivering measurement-based mental health care

Automatically gather client data, measure client outcomes, and get insights at the point of care to make more informed treatment decisions.

Request a Demo
Blueprint digital platform preview